Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor

被引:122
|
作者
Mirzabekov, T
Bannert, N
Farzan, M
Hofmann, W
Kolchinsky, P
Wu, LJ
Wyatt, R
Sodroski, J
机构
[1] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA
[4] Leukosite Inc, Cambridge, MA 02142 USA
关键词
D O I
10.1074/jbc.274.40.28745
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Seven-transmembrane segment, G protein-coupled receptors (GPCRs) play important roles in many biological processes in which pharmaceutical intervention may be useful. High level expression and native purification of GPCRs are important steps in the biochemical and structural characterization of these molecules. Here, we describe enhanced mammalian cell expression and purification of a codon-optimized variant of the chemokine receptor CCR5, a GPCR that plays a central role in the entry of the human immunodeficiency virus-1 (HIV-1) into immune cells. CCR5 could be solubilized in its native state as determined by its ability to be precipitated by 2D7, a conformation-dependent anti-CCR5 antibody, and by the HIV-1 gp120 envelope glycoprotein. The 2D7 antibody recognized immature and mature forms of CCR5 equally, whereas gp120 preferentially recognized the mature form, a result that underscores a role for posttranslational modification of CCR5 in its HIV-1 coreceptor function. The methods described herein contribute to the analysis of CCR5 and are likely to be applicable to many other GPCRs.
引用
收藏
页码:28745 / 28750
页数:6
相关论文
共 50 条
  • [21] CCR5 inhibitors in HIV-1 therapy
    Dorr, Patrick
    Perros, Manos
    EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (11) : 1345 - 1361
  • [22] Analysis of the prevalence of CCR5 coreceptor antagonist resistance mutations among HIV-1 variants in Russia
    Vasilyev, A. V.
    Kazennova, E. V.
    Bobkova, M. R.
    VOPROSY VIRUSOLOGII, 2011, 56 (03) : 32 - 37
  • [23] Characterization of mutant envelope glycoprotein of HIV-1 that utilizes N-terminally truncated CCR5 coreceptor for virus entry
    Melikian, Gregory
    Platt, Emily
    Kabat, David
    BIOPHYSICAL JOURNAL, 2007, : 243A - 243A
  • [24] Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection
    Abad, JL
    González, MA
    del Real, G
    Mira, E
    Mañes, S
    Serrano, F
    Bernad, A
    MOLECULAR THERAPY, 2003, 8 (03) : 475 - 484
  • [25] Porphyromonas gingivalis selectively up-regulates the HIV-1 coreceptor CCR5 in oral Keratinocytes
    Giacaman, Rodrigo A.
    Nobbs, Angela H.
    Ross, Karen F.
    Herzberg, Mark C.
    JOURNAL OF IMMUNOLOGY, 2007, 179 (04): : 2542 - 2550
  • [26] High frequency of the HIV-1 protective CCR5 Δ32 deletion in native Estonians
    Kalev, I
    Mikelsaar, AV
    Beckman, L
    Tasa, G
    Pärlist, P
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2000, 16 (12) : 1107 - 1109
  • [27] High frequency of the HIV-1 protective CCR5 Δ32 deletion in native Estonians
    I. Kalev
    A.-V. Mikelsaar
    L. Beckman
    G. Tasa
    P. Pärlist
    European Journal of Epidemiology, 2000, 16 : 1107 - 1109
  • [28] Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection
    Yost, Raymond
    Pasquale, Timothy R.
    Sahloff, Eric G.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (08) : 715 - 726
  • [29] HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: Independence from G protein signaling and importance of coreceptor downmodulation
    Alkhatib, G
    Locati, M
    Kennedy, PE
    Murphy, PM
    Berger, EA
    VIROLOGY, 1997, 234 (02) : 340 - 348
  • [30] Choosing CCR5 or Rev siRNA in HIV-1
    Arteaga, HJ
    Hinkula, J
    van Dijk-Härd, I
    Dilber, MS
    Wahren, B
    Christensson, B
    Mohamed, AJ
    Smith, CIE
    NATURE BIOTECHNOLOGY, 2003, 21 (03) : 230 - 231